# EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Source: https://onco.cc/trials/nct06525298/  
OnCo record `nct06525298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Olaparib and Trastuzumab deruxtecan in advanced solid tumours, run by Eisbach Bio GmbH, now recruiting.

## Summary

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors is a phase 1/2 interventional study registered as NCT06525298 by Eisbach Bio GmbH, with 144 participants planned, started 2024-09-09 and due to reach its primary completion in 2027-09. Interventions recorded: EIS-12656, Olaparib and Trastuzumab deruxtecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06525298
- Phase: 1/2
- Setting: A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors
- Sponsor: Eisbach Bio GmbH
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT06525298: https://clinicaltrials.gov/study/NCT06525298

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)

---
JSON: https://onco.cc/api/v1/entities/nct06525298.json